Literature DB >> 27009743

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Alexander Drilon1.   

Abstract

MET exon 14 alterations are a diverse group of mutations, many of which disrupt splice acceptor or donor sites leading to exon 14 skipping, impaired receptor degradation, and oncogenic transformation. These alterations are clinically targetable with MET-directed therapy. Clin Cancer Res; 22(12); 2832-4. ©2016 AACRSee related article by Tong et al., p. 3048. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27009743      PMCID： PMC4911276          DOI： 10.1158/1078-0432.CCR-16-0229

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

Authors:  P Peschard; T M Fournier; L Lamorte; M A Naujokas; H Band; W Y Langdon; M Park
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

2.  Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Authors:  Monica Kong-Beltran; Somasekar Seshagiri; Jiping Zha; Wenjing Zhu; Kaumudi Bhawe; Nerissa Mendoza; Thomas Holcomb; Kanan Pujara; Jeremy Stinson; Ling Fu; Christophe Severin; Linda Rangell; Ralph Schwall; Lukas Amler; Dineli Wickramasinghe; Robert Yauch
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

3.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

4.  Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects.

Authors:  S Tuffery-Giraud; S Chambert; J Demaille; M Claustres
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

5.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Authors:  Mark M Awad; Geoffrey R Oxnard; David M Jackman; Daniel O Savukoski; Dimity Hall; Priyanka Shivdasani; Jennifer C Heng; Suzanne E Dahlberg; Pasi A Jänne; Suman Verma; James Christensen; Peter S Hammerman; Lynette M Sholl
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

Review 6.  The connection between splicing and cancer.

Authors:  Anabella Srebrow; Alberto R Kornblihtt
Journal:  J Cell Sci       Date:  2006-07-01       Impact factor: 5.285

7.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Authors:  Patrick C Ma; Ramasamy Jagadeeswaran; Simha Jagadeesh; Maria S Tretiakova; Vidya Nallasura; Edward A Fox; Mark Hansen; Erik Schaefer; Katsuhiko Naoki; Alan Lader; William Richards; David Sugarbaker; Aliya N Husain; James G Christensen; Ravi Salgia
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

Review 8.  RNA mis-splicing in disease.

Authors:  Marina M Scotti; Maurice S Swanson
Journal:  Nat Rev Genet       Date:  2015-11-23       Impact factor: 53.242

9.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Authors:  Xuewen Liu; Yuxia Jia; Mark B Stoopler; Yufeng Shen; Haiying Cheng; Jinli Chen; Mahesh Mansukhani; Sanjay Koul; Balazs Halmos; Alain C Borczuk
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

10.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Authors:  Joanna H Tong; Sai F Yeung; Anthony W H Chan; Lau Y Chung; Shuk L Chau; Raymond Wai Ming Lung; Carol Y Tong; Chit Chow; Edith K Y Tin; Yau H Yu; Hui Li; Yi Pan; Wing P Chak; Calvin S H Ng; Tony S K Mok; Ka F To
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531
View more
  10 in total

1.  Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping.

Authors:  Joon Young Hur; Bo Mi Ku; Joon Ho Shim; Hyun Ae Jung; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

3.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

Review 4.  Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.

Authors:  Joshua K Sabari; Fernando Santini; Isabella Bergagnini; W Victoria Lai; Kathryn C Arbour; Alexander Drilon
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

5.  Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Authors:  Magda Bahcall; Mark M Awad; Lynette M Sholl; Frederick H Wilson; Man Xu; Stephen Wang; Sangeetha Palakurthi; Jihyun Choi; Elena V Ivanova; Giulia C Leonardi; Bryan C Ulrich; Cloud P Paweletz; Paul T Kirschmeier; Masayuki Watanabe; Hideo Baba; Mizuki Nishino; Rebecca J Nagy; Richard B Lanman; Marzia Capelletti; Emily S Chambers; Amanda J Redig; Paul A VanderLaan; Daniel B Costa; Yu Imamura; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2018-08-02       Impact factor: 12.531

Review 6.  MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.

Authors:  Mark A Socinski; Nathan A Pennell; Kurtis D Davies
Journal:  JCO Precis Oncol       Date:  2021-04-13

Review 7.  Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

Authors:  Alia Daoud; Quincy S Chu
Journal:  Front Oncol       Date:  2017-09-29       Impact factor: 6.244

8.  Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.

Authors:  Tianli Cheng; Zhongping Gu; Danni Song; Sisi Liu; Xiaoling Tong; Xue Wu; Zhifeng Lin; Wei Hong
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

9.  Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.

Authors:  Takashi Seto; Kadoaki Ohashi; Shunichi Sugawara; Makoto Nishio; Masayuki Takeda; Keisuke Aoe; Sanae Moizumi; Satoshi Nomura; Takeshi Tajima; Toyoaki Hida
Journal:  Cancer Sci       Date:  2021-02-24       Impact factor: 6.716

Review 10.  [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].

Authors:  Limei Yin; You Lu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.